[en]
Purpose of Review
Chimeric antigen receptor (CAR) T cells are a form of adoptive therapy employing autologous T cells engineered with an artificial receptor, able to recognize tumor antigens through an HLA-independent mechanism. We will review data on safety and efficacy outcomes with CAR T cell therapy in lymphomas.Recent Findings
Multicenter trials evaluating three CAR T cell products targeting CD19 have shown that they are highly effective and induce durable remissions in a substantial proportion of patients with relapsed or refractory aggressive B cell non-Hodgkin lymphoma (NHL). The most common toxicities were cytokine release syndrome and neurotoxicity.Summary
Two anti-CD19 CAR T cell products were approved by the FDA for the treatment of patients with relapsed or refractory aggressive B cell NHL. Ongoing research is aimed at investigating their use in earlier lines of therapy and in other B cell lymphomas, improving CAR T cell efficacy and safety, and evaluating novel targets.Journal
Current Oncology Reports; ISSN 1523-3790; 
; v. 21(5); p. 1-7
; v. 21(5); p. 1-7
[en] We report the long-term results of a prospective trial conducted to determine the efficacy and safety of radiation therapy (RT) alone in treating localized mucosa-associated lymphoid tissue (MALT) lymphoma.
Journal
International Journal of Radiation Oncology, Biology and Physics; ISSN 0360-3016; ; CODEN IOBPD3; v. 109(5); p. 1414-1420
; CODEN IOBPD3; v. 109(5); p. 1414-1420